Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | CXCR6 | O00574 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11165630 | 1.00 | DRD3 (1.00) | DRD3CXCR6CXCR4OPRK1DRD2 | |
| SCHEMBL11172665 | 0.92 | DRD3 (0.86) | DRD3CXCR6CXCR4OPRK1 | |
| SCHEMBL11166603 | 0.92 | DRD3 (0.86) | DRD3CXCR6CXCR4OPRK1 | |
| Tropapride SCHEMBL2110411 | 0.88 | DRD3 (0.79) | DRD3DRD2 | |
| SCHEMBL11166945 | 0.88 | DRD3 (0.78) | DRD3CXCR6CXCR4OPRK1DRD2 | |
| SCHEMBL11167422 | 0.85 | DRD3 (0.74) | DRD3CXCR6CXCR4OPRK1DRD2 | |
| SCHEMBL11204438 | 0.83 | DRD3 (0.72) | DRD3CXCR6CXCR4OPRK1 | |
| SCHEMBL11297735 | 0.82 | DRD3 (0.70) | DRD3DRD2 | |
| SCHEMBL3365934 | 0.82 | DRD3 (1.00) | DRD3 | |
| SCHEMBL8126666 | 0.78 | SIGMAR1 (0.67) | DRD3CXCR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0083737-A1 | N-azabicycloalkane benzamides, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-07-20 | — | — | EP | claimed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-0083737-A1 | N-azabicycloalkane benzamides, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | DRD3 80/4885CXCR6 1831/4885CXCR4 488/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | DRD3 2912/4885CXCR6 1037/4885CXCR4 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.